103 related articles for article (PubMed ID: 11908868)
1. Expression of Bcl-2, Bcl-x, and Bax proteins in astrocytomas in relation to patient survival.
Daido S; Tamiya T; Ono Y; Terada K; Mizumatsu S; Ohmoto T
Brain Tumor Pathol; 2001; 18(2):123-9. PubMed ID: 11908868
[TBL] [Abstract][Full Text] [Related]
2. High cyclin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas.
Tamiya T; Mizumatsu S; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Acta Neuropathol; 2001 Apr; 101(4):334-40. PubMed ID: 11355304
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
4. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status.
Newcomb EW; Bhalla SK; Parrish CL; Hayes RL; Cohen H; Miller DC
Acta Neuropathol; 1997 Oct; 94(4):369-75. PubMed ID: 9341939
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
[TBL] [Abstract][Full Text] [Related]
6. Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors.
Hara A; Hirose Y; Yoshimi N; Tanaka T; Mori H
Neurol Res; 1997 Dec; 19(6):623-8. PubMed ID: 9427964
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
8. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas.
Varela M; Ranuncolo SM; Morand A; Lastiri J; De Kier Joffé EB; Puricelli LI; Pallotta MG
J Surg Oncol; 2004 Apr; 86(1):34-40. PubMed ID: 15048678
[TBL] [Abstract][Full Text] [Related]
9. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
Deininger MH; Weller M; Streffer J; Meyermann R
Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
[TBL] [Abstract][Full Text] [Related]
10. Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal.
Martin S; Toquet C; Oliver L; Cartron PF; Perrin P; Meflah K; Cuillère P; Vallette FM
J Neurooncol; 2001 Apr; 52(2):129-39. PubMed ID: 11508812
[TBL] [Abstract][Full Text] [Related]
11. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer.
Baekelandt M; Holm R; Nesland JM; Tropé CG; Kristensen GB
J Clin Oncol; 2000 Nov; 18(22):3775-81. PubMed ID: 11078490
[TBL] [Abstract][Full Text] [Related]
12. Cellular proliferation in pilocytic and diffuse astrocytomas.
Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
[TBL] [Abstract][Full Text] [Related]
13. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
14. Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
Shrestha P; Saito T; Hama S; Arifin MT; Kajiwara Y; Yamasaki F; Hidaka T; Sugiyama K; Kurisu K
Cancer; 2007 Mar; 109(5):949-56. PubMed ID: 17262828
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas.
Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Otsuka Y; Yamaguchi M; Ohnishi H; Ohtaki S; Noshiro S; Ookawa S; Mikami T; Mikuni N; Honmou O
J Neurosurg Sci; 2018 Jun; 62(3):239-244. PubMed ID: 28079349
[TBL] [Abstract][Full Text] [Related]
16. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
18. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas.
Thotakura M; Tirumalasetti N; Krishna R
J Cancer Res Ther; 2014; 10(3):641-5. PubMed ID: 25313753
[TBL] [Abstract][Full Text] [Related]
19. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
Saito T; Arifin MT; Hama S; Kajiwara Y; Sugiyama K; Yamasaki F; Hidaka T; Arita K; Kurisu K
J Neurooncol; 2007 Apr; 82(2):193-8. PubMed ID: 17151933
[TBL] [Abstract][Full Text] [Related]
20. Expression of the small heat shock protein (hsp) 27 in human astrocytomas correlates with histologic grades and tumor growth fractions.
Khalid H; Tsutsumi K; Yamashita H; Kishikawa M; Yasunaga A; Shibata S
Cell Mol Neurobiol; 1995 Apr; 15(2):257-68. PubMed ID: 8590455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
